Protocol for venoarterial ExtraCorporeal Membrane Oxygenation to reduce morbidity and mortality following bilateral lung TransPlantation: the ECMOToP randomised controlled trial

Jonathan Messika,Philippine Eloy,David Boulate,Aude Charvet,Julien Fessler,Jacques Jougon,Philippe Lacoste,Olaf Mercier,Philippe Portran,Hadrien Roze,Edouard Sage,Jacques Thes,Francois Tronc,Mickael Vourc'h,Philippe Montravers,Yves Castier,Herve Mal,Pierre Mordant,Investigators from the ECMOToP Study group,Nassima Si Mohammed,Pierre Cerceau,Antoine Girault,Arnaud Roussel,Elie Kantor,Brice Lortat-Jacob,Sylvain Jean-Baptiste,Vincent Bunel,Isabelle Pavlakovic,Delphine Chesnel,Léa Didier,Matthias Jacquet Lagreze,Eva Chatron,Claire Merveilleux Du Vignaux,Gabrielle Drevet,Jean Michel Maury,Valentin Soldea,Xavier Demant,Julie Macey,Christelle Pellerin,Jérôme Ridolfo,Elodie Blanchard,Clément Boisselier,Claire Bon,Benjamin Chevalier,Eloïse Gallo,Benjamin Repusseau,Arnaud Rodriguez,Regisse Seramondi,Matthieu Thumerel,Gaelle Dauriat,Amélie Delaporte,Samuel Dolidon,Jerome Estephan,Sylvain Diop,Dominique Fabre,Elie Fadel,Severine Feuillet,Pierre Gazengel,Avit Guirimand,Iolanda Ion,Christian Ionescu,Justin Issard,Jérome Le Pavec,Chahine Medraoui,Jean-Baptiste Menager,Delphine Mitilian,Andy Musat,Marwan Nader,Geoffrey Brioude,Xavier Djourno,Ambroise Labarriere,Pierre Mora,Bruno Pastene,Adrien Rivory,Pascal-Alexandre Thomas,Julien Cadiet,Nicolas Groleau,Thierry Lepoivre,Antoine Roux,Sandra de Miranda,Clément Picard,Laurence Beaumont,Olivier Brugière,Sylvie Colin de Verdière,Abdul-Momen Hamid,François Parquin,Amer Hamdan,Benjamin Zuber,Charles Cerf,Jérôme Devaquet,Richard Galliot,Guillaume Tachon,Nicolas Mayenco-Cardenal,Mathilde Phillips-Houlbracq,David Cortier,Johanna Cohen,Alexis Paternot,Ciprian Pricopi,Francesco Cassiano,Matthieu Glorion,Julien De Wolf,Chloé Mimbimi,Morgan Le Guen,Virginie Dumans,Sébastien Jacqmin,Michael Finet,Sindia Goncalves,Louis Grosz,Charles Hickel,Julien Josserand,Julien Richard,Gaëlle Weisenburger,Aurélie Snauwaert,Sandrine Boudinet,Enora Atchade,Messika,J.,Eloy,P.,Boulate,D.,Charvet,A.,Fessler,J.,Jougon,J.,Lacoste,P.,Mercier,O.,Portran,P.,Roze,H.,Sage,E.,Thes,J.,Tronc,F.,Vourc'h,M.,Montravers,P.,Castier,Y.,Mal,H.,Mordant,P.,Mohammed,Cerceau,Girault,Roussel,Kantor,Lortat-Jacob,Jean-Baptiste,Bunel,Pavlakovic,Chesnel,Didier,Lagreze,Chatron,Vignaux,Drevet,Maury,Soldea,Demant,Macey,Pellerin,Ridolfo,Blanchard,Boisselier,Bon,Chevalier,Gallo,Repusseau,Rodriguez,Seramondi,Thumerel,Dauriat,Delaporte,Dolidon,Estephan,Diop,Fabre,Fadel,Feuillet,Gazengel,Guirimand,Ion,Ionescu,Issard,Pavec,Medraoui,Menager,Mitilian,Musat,Nader,Brioude,Djourno,Labarriere,Mora,Pastene,Rivory,Thomas,Cadiet,Groleau,Lepoivre,Roux,Miranda,Picard,Beaumont,Brugiere,Verdiere,Hamid,Parquin,Hamdan,Zuber,Cerf,Devaquet,Galliot,Tachon,Mayenco-Cardenal,Phillips-Houlbracq,Cortier,Cohen,Paternot,Pricopi,Cassiano,Glorion,Wolf,Mimbimi,Guen,Dumans,Jacqmin,Finet,Goncalves,Grosz,Hickel,Josserand,Richard,Weisenburger,Snauwaert,Boudinet,Atchade

DOI: https://doi.org/10.1136/bmjopen-2023-077770

IF: 3.006

2024-03-07

BMJ Open

Abstract:Introduction Lung transplantation (LTx) aims at improving survival and quality of life for patients with end-stage lung diseases. Venoarterial extracorporeal membrane oxygenation (VA-ECMO) is used as intraoperative support for LTx, despite no precise guidelines for its initiation. We aim to evaluate two strategies of VA-ECMO initiation in the perioperative period in patients with obstructive or restrictive lung disease requiring bilateral LTx. In the control 'on-demand' arm, high haemodynamic and respiratory needs will dictate VA-ECMO initiation; in the experimental 'systematic' arm, VA-ECMO will be pre-emptively initiated. We hypothesise a 'systematic' strategy will increase the number of ventilatory-free days at day 28. Methods and analysis We designed a multicentre randomised controlled trial in parallel groups. Adult patients with obstructive or restrictive lung disease requiring bilateral LTx, without a formal indication for pre-emptive VA-ECMO before LTx, will be included. Patients with preoperative pulmonary hypertension with haemodynamic collapse, ECMO as a bridge to transplantation, severe hypoxaemia or hypercarbia will be secondarily excluded. In the systematic group, VA-ECMO will be systematically implanted before the first pulmonary artery cross-clamp. In the on-demand group, VA-ECMO will be implanted intraoperatively if haemodynamic or respiratory indices meet preplanned criteria. Non-inclusion, secondary exclusion and VA-ECMO initiation criteria were validated by a Delphi process among investigators. Postoperative weaning of ECMO and mechanical ventilation will be managed according to best practice guidelines. The number of ventilator-free days at 28 days (primary endpoint) will be compared between the two groups in the intention-to-treat population. Secondary endpoints encompass organ failure occurrence, day 28, day 90 and year 1 vital status, and adverse events. Ethics and dissemination The sponsor is the Assistance Publique–Hôpitaux de Paris. The ECMOToP protocol version 2.1 was approved by Comité de Protection des Personnes Ile de France VIII. Results will be published in international peer-reviewed medical journals. Trial registration number NCT05664204.

medicine, general & internal

What problem does this paper attempt to address?

This paper attempts to address the issue of how to reduce postoperative morbidity and mortality in bilateral lung transplantation surgery by using Venoarterial Extracorporeal Membrane Oxygenation (VA-ECMO). Specifically, the study aims to evaluate the perioperative effects of two VA-ECMO initiation strategies: one is the "on-demand" initiation strategy, which starts VA-ECMO when high hemodynamic or respiratory needs arise; the other is the "systematic" initiation strategy, which prophylactically starts VA-ECMO before the surgery begins. The study hypothesizes that the "systematic" initiation strategy will increase the number of ventilator-free days within 28 days post-surgery.

The primary objective of the study is to evaluate the effectiveness of the systematic early initiation of VA-ECMO strategy compared to the on-demand initiation strategy guided by hemodynamic and respiratory parameters in increasing the number of ventilator-free days within 28 days post-surgery in bilateral lung transplantation. Secondary objectives include investigating the impact of the systematic VA-ECMO strategy compared to the on-demand initiation strategy on the following aspects:
- Incidence of grade 3 primary graft dysfunction (PGD) within 72 hours post-surgery
- All-cause mortality on day 28, day 90, and within 1 year post-surgery
- Incidence of ECMO-related adverse events within 28 days post-surgery
- Incidence of ventilator-associated pneumonia within 28 days post-surgery
- Incidence of intraoperative hemodynamic failure
- Incidence of hemodynamic failure within 28 days post-surgery
- Incidence of acute kidney injury (KDIGO stage 3) within 28 days post-surgery
- Requirement for red blood cell transfusion within 28 days post-surgery
- Number of ECMO-free days within 28 days post-surgery
- Length of stay in the intensive care unit (ICU)
- Length of hospital stay
- Incidence of bronchial complications requiring bronchoscopic intervention from transplantation to 1 year
- Forced expiratory volume in 1 second (FEV1) at 1 year

This study is designed as a multicenter, randomized, open-label, controlled superiority clinical trial, aiming to compare the effectiveness of the two strategies under real-world clinical practice conditions.